Projects

Head of the Department of Experimental Hypertension
RNDr. Iveta Bernátová, DrSc.

International

Current
  • Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases
    Program: COST
    Duration: 19. 10. 2021 – 18. 10. 2025
Finished
  • Study the role of iron oxide nanoparticles in a model of hypertension and comorbid Alzheimer\'s disease
    Program: Inter-academic agreement
    Duration: 1. 1. 2018 – 31. 12. 2020
  • Stress-induced pressor responses: endothelial factors vs. central regulation of sympathetic tone
    Program: Inter-academic agreement
    Duration: 1. 1. 2016 – 31. 12. 2017
  • Effect of natural polyphenols on the development and maintenance of experimental hypertension and remodelling of cardiovascular system
    Program: Inter-institute agreement
    Duration: 1. 10. 2004 – 30. 9. 2013

National

Current
  • Identification of stress-induced alterations in expression of NRF2 target genes in rat models of prehypertension: the effect of comorbid hypertriglyceridemia and dimethyl fumarate treatment
    Program: SRDA
    Duration: 1. 7. 2023 – 30. 6. 2027
  • Cardiovascular protection mediated by alpha 1 AMPK against metabolic syndrome-mediated endothelial dysfunction - identifying new risk factors
    Program: SRDA
    Duration: 1. 7. 2023 – 30. 6. 2027
  • Hyperuricemia in various comorbidities of the metabolic syndrome - mechanisms of the effect of uric acid on endothelial function and erythrocyte deformability.
    Program: VEGA
    Duration: 1. 1. 2021 – 31. 12. 2024
  • SQUID magnetometry of nano- and microparticles, nanocolloids and nanostructures in new applications in the field of biomedicine and materials research associated with the development of new measurement methods and procedures
    Program: VEGA
    Duration: 1. 1. 2021 – 31. 12. 2024
  • Role of nuclear factor NRF2-mediated signalling in iron metabolism regulation during stress
    Program: VEGA
    Duration: 1. 1. 2021 – 31. 12. 2024
Finished
  • New perspectives in the treatment of cardiovascular complications associated with COVID-19
    Program: SRDA
    Duration: 16. 9. 2020 – 31. 12. 2021
  • Research of magnetic forms of iron in development of cardiovascular diseases and behavioural disorders
    Program: SRDA
    Duration: 1. 7. 2017 – 30. 6. 2021
  • Mechanisms involved in uric acid-induced endothelial dysfunction depending on the age and genetic predisposition to hypertension
    Program: VEGA
    Duration: 1. 1. 2017 – 31. 12. 2020
  • Effect of ultrasmall superparamagnetic iron oxide nanoparticles on the cardiovascular system of rats with high blood pressure
    Program: VEGA
    Duration: 1. 1. 2017 – 31. 12. 2020
  • Research on possibilities and development of SQUID magnetometry for selected applications in biomedicine and material research
    Program: VEGA
    Duration: 1. 1. 2017 – 31. 12. 2020
  • Study of regulation of radical and cellular signaling during hypertension and influence of novel therapies on this signaling.
    Program: SRDA
    Duration: 1. 10. 2013 – 30. 9. 2017
  • Effect of aging on the endothelial function in experimental hypertension
    Program: Other projects
    Duration: 17. 4. 2014 – 17. 4. 2017
  • Epicatechin in prevention of early development of primary hypertension: mechanisms of action in the cardiovascular and central nervous systems
    Program: VEGA
    Duration: 1. 1. 2014 – 31. 12. 2016
  • Development of SQUID Gradiometric and Susceptometric Methods for Iron Homeostasis Related Bio-Applications
    Program: VEGA
    Duration: 1. 1. 2013 – 31. 12. 2016
  • Gender differences in etiopathogenesis of social stress-related cardiovascular and behavioral disorders in individuals with predisposition to hypertension
    Program: SRDA
    Duration: 1. 5. 2011 – 30. 10. 2014
  • Social stress as a risk factor of early development of hypertension in predisposed individuals
    Program: VEGA
    Duration: 1. 1. 2010 – 31. 12. 2013
  • Centre of Excellence for Research and Development of Constructive Composite Materials II
    Program: EU Structural Funds Research & Development
    Duration: 1. 9. 2009 – 30. 6. 2013
  • Effect of natural compounds on the action of endogenous and exogenous oxidants
    Program: VEGA
    Duration: 1. 1. 2009 – 31. 12. 2011
  • In-vivo antioxidant gene therapy in the therapy of hypertension
    Program: VEGA
    Duration: 1. 1. 2008 – 31. 12. 2010
  • Hypertension and diabetes as the parts of metabolic syndrome: the effects of antioxidant therapy
    Program: SRDA
    Duration: 1. 6. 2008 – 31. 12. 2010
  • Long-term low dose L-NAME treatment:Possibility to improve the vascular function in borderline hypertension?
    Program: VEGA
    Duration: 1. 1. 2007 – 31. 12. 2009
  • Protection of the heart against malignant arrhythmias and heart failure.
    Program: SRDA
    Duration: 2. 5. 2006 – 30. 4. 2009
  • Procection of the heart against malignant arrhythmias and heart failure
    Program: SRDA
    Duration: 1. 2. 2006 – 31. 12. 2008
  • Pharmacological treatment of hypertension in early stage of its development
    Program: VEGA
    Duration: 1. 1. 2006 – 1. 12. 2008
  • Role of bioflavonoids in prevention of social stress-induced hypertension
    Program: SRDA
    Duration: 1. 1. 2005 – 31. 12. 2007
  • Ischaemia and reperfusion in experimental diabetes type 2 and possibilities of pharmacological management
    Program: VEGA
    Duration: 1. 1. 2005 – 1. 12. 2007
  • The interaction of stress and genetic factors in the etiology of high blood pressure and behavioral failure: the role of nitric oxide
    Program: VEGA
    Duration: 1. 1. 2004 – 31. 12. 2006
Employees